The aim of this study was to examine if maternal plasma concentrations of soluble vascular endothelial growth factor receptor (sVEGFR)-2 change prior to the diagnosis of preeclampsia.
P
reeclampsia is one of the leading causes of perinatal and maternal mortality. Despite several decades of research, the pathophysiology of this syndrome is still unclear. [1] [2] [3] [4] Maynard et al 5 proposed that preeclampsia is an antiangiogenic state characterized by an increased plasma concentration of soluble vascular endothelial growth factor (VEGF) receptor (sVEGFR)-1 and a decrease in plasma concentration of placental growth factors (PlGF) as well as VEGF. Since then, studies of angiogenic and antiangiogenic factors in preeclampsia have gained increasing attention. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] VEGF is an endothelial cell-specific growth factor with potent angiogenic properties. Its function is to promote endothelial cell proliferation, migration, 19, 20 and prevent endothelial cell apoptosis. 21 While VEGFR-1 is considered a decoy receptor, VEGFR-2 is the major mediator of the mitogenic, angiogenic, permeability-enhancing, and endothelial survival effects of VEGF.
The contribution of sVEGFR-1 to the maternal syndrome of preeclampsia is thought to be, at least in part, related to its inhibition of VEGF stimulation of the endothelium-dependent nitric oxide system. 5 Plasma sVEGFR-1 concentration has been found to be elevated in preeclampsia both prior to 6, 12, 13, [22] [23] [24] [25] [26] [27] [28] [29] and at the time of the diagnosis of preeclampsia. 5, 7, 9, [30] [31] [32] [33] [34] The natural form of sVEGFR-2 has recently been detected in human plasma, 35 although the use of a recombinant form or adenovirus encoding for sVEGFR-2 gene in cancer therapy has been under investigation for quite some time. [36] [37] [38] [39] Under experimental conditions, this protein can bind to VEGF 35 and its recombinant form has antiangiogenic activity. 37, 40 The role of sVEGFR-2 in human health and diseases is unclear. However, recent studies have evaluated its potential as a surrogate biomarker for tumor progression in malignant melanoma, myelodysplastic syndrome, 42 and acute leukemia. 43, 44 In nonmalignant conditions, plasma sVEGFR-2 concentration is lower in patients with systemic lupus erythematosus disease 45 and dengue hemorrhagic fever 46 compared to healthy controls. Similarly, patients with preeclampsia or those with isolated small-for-gestational-age fetuses at the time of clinical diagnosis have lower plasma concentrations of sVEGFR-2 than healthy pregnant women. [47] [48] [49] The objective of this study was to examine if the maternal plasma concentrations of sVEGFR-2 change prior to the clinical diagnosis of preeclampsia.
MATERIALS AND METHODS

Study design
A longitudinal nested case-control study was conducted by searching our clinical database and bank of biologic samples from 2002 through 2006. Patients with preeclampsia (n ϭ 40) and healthy pregnant women (n ϭ 160) were included. Exclusion criteria were: (1) chronic hypertension; (2) known major fetal or chromosomal anomaly; and (3) multiple gestations. All women were enrolled in the prenatal clinic at the Sotero del Rio Hospital, Santiago, Chile, and followed up until delivery.
Subjects were included only if they had plasma samples available at least once before and after 24 weeks of gestation (unless delivered Ͻ28 weeks). All patients had a minimum of 3 samples during pregnancy (ranging from 3-7 samples). Plasma samples were selected once from each patient at the following 7 intervals: 6-14; 15-19; 20-24; 25-27; 28-31; 32-36; and Ն37 weeks of gestation. The earliest sample for each interval is used. Samples collected after the clinical diagnosis of preeclampsia were not included.
Clinical definition
Preeclampsia was defined as hypertension (systolic blood pressure Ն140 mm Hg or diastolic blood pressure Ն90 mm Hg on at least 2 occasions, 4 hours-1 week apart) and proteinuria. 50 Severe preeclampsia was defined as previously described. 49 Early-onset preeclampsia was defined as a diagnosis Յ34 weeks of gestation. 51 Pregnant women were considered normal if they had no medical, obstetric, or surgical complications, and delivered a healthy term (Ն37 weeks) infant whose birthweight was appropriate for gestational age (10th-90th percentile). 52 The collection and utilization of the samples was approved by both the Human Investigation Committee of the Sotero del Rio Hospital, Santiago, Chile (a major affiliate of the Catholic University of Santiago) and the institutional review board of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (National Institutes of Health, Department of Health and Human Services). Many of these samples were used in previous studies.
Sample collection and immunoassays
Venipunctures were performed and blood was collected into tubes containing EDTA. Samples were centrifuged and stored at Ϫ70°C. Maternal plasma concentrations of sVEGFR-2 were determined by immunoassays (R&D Systems, Minneapolis, MN) as previously described. 49 The interassay and intraassay coefficients of variation were 2% and 4%, respectively. The sensitivity was 19 pg/mL.
Statistical analysis
Cross-sectional analysis Kruskal-Wallis and post hoc MannWhitney U tests were utilized to determine the differences of the median among and between groups. Fisher's exact and 2 tests were employed for comparisons of proportions. Logistic regression was applied to examine the association between low plasma concentrations of sVEGFR-2 (defined as plasma sVEGFR-2 concentrations below the first quartile of normal pregnancy) and the development of preeclampsia in samples obtained prior to the clinical diagnosis after adjusting for potential confounders. The statistics package used was SPSS V.15 (SPSS Inc, Chicago, IL). A P value of Ͻ .05 was considered significant.
Longitudinal analysis
Changes in the plasma concentrations of sVEGFR-2 over time and between groups were examined using a linear mixed effects model (fixed effects ϩ random effects). The fixed effects were the diagnosis (a factor with 2 levels: normal pregnancy and preeclampsia), the linear and quadratic effects of gestational age, the interaction term between the diagnosis and gestational 
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Research Obstetrics www.AJOG.org age, plus several covariates including: maternal age, body mass index, smoking, nulliparity, previous preeclampsia, and sample storage time. The random effects were the patient identification numbers, therefore allowing examination of the deviation of each individual from the average profile of each diagnostic group and accounting for the unknown variability among patients. The model was fitted to the transformed plasma concentration (log10 of [1 ϩ concentration]) of the analyte. This logarithmic transformation was employed to improve normality of the data and stabilize variance across the entire range of gestational age. Statistical significance of fixed effects was assessed using t scores, and a P value Ͻ .05 was considered significant. The analysis was performed using the nonlinear mixed effect model package of the R statistical environment (www. r-project.org). 
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To identify the gestational age at which the difference in the median concentration between groups became significant, a moving window approach was used. Unlike in the cross-sectional study, where the limits of the intervals were predetermined, in the moving window approach, the number of data points was fixed to 200, 250, and 300 for each window. All observations were sorted as a function of the gestational age in ascending order. A set of 200-300 data points was chosen starting with the smallest gestation age and moving up the list. A Wilcoxon test was used to determine if there was significant difference between the 2 groups in each window of gestational age. The procedure was repeated until the point when the difference between groups remained significant (either for P Ͻ .05 or P Ͻ .01) in the current window and all consecutive ones. The median gestational age in the current window recorded.
RESULTS
Clinical characteristics of the study population are displayed in Table 1 . The gestational age at which preeclampsia was diagnosed varied. Three patients had hypertension and proteinuria at 25-27 weeks, 4 at 28-31 weeks, 8 at 32-36 weeks, and 25 at term (Ն37 weeks). There were no significant differences in the median gestational age at which venipuncture was performed by the interval window between the group of patients who eventually developed preeclampsia and the control group except in 1 gestational age interval (32-36 weeks, P ϭ .04) ( Table 2 ).
Plasma sVEGFR-2 concentrations are decreased prior to the clinical manifestation of preeclampsia: forward cross-sectional analysis
No significant difference in the median plasma sVEGFR-2 concentration between patients with preeclampsia and healthy pregnant women was observed at 6-14, 20-24, and 25-27 weeks of gestation (all P Ͼ .05) ( Table 2) . However, at 15-19, 28-31, and 32-36 weeks of gestation, the median plasma sVEGFR-2 concentrations in women who subsequently developed preeclampsia were significantly lower than in healthy pregnant women (all P Ͻ .05) ( Table 2) . Patients with preeclampsia at the time of the clinical diagnosis had a significantly lower median plasma sVEGFR-2 concentration than those before clinical manifestation at 25-27, 28-31, and 32-36 weeks of gestation (P ϭ .03, P ϭ .02, and P ϭ .04, respectively) and lower than healthy pregnant women at 25-27, 28-31, and 32-36 weeks and at term gestation (P ϭ .02, P ϭ .02, P ϭ .002, and P ϭ.009, respectively) ( Table 2) .
To examine the association between low plasma concentrations of sVEGFR-2 (Table 3) .
Plasma sVEGFR-2 concentrations are decreased prior to the clinical manifestation of preeclampsia: longitudinal analysis
Patients who subsequently developed preeclampsia had a different profile (plasma concentration over time) of plasma sVEGFR-2 concentration from patients with normal pregnancies after adjusting for potential confounders (P Ͻ .05) ( Table 4) . When the plasma concentrations of sVEGFR-2 estimated from the mixed effects model were plotted against the observed plasma sVEGFR-2 concentrations, there was a good correlation between the two (R 2 ϭ 0.75) (Figure 1) . The plasma sVEGFR-2 concentration was lower in women destined to develop preeclampsia than in healthy pregnant women from approximately 16-20 weeks of gestation. The difference became statistically significant (P Ͻ .05) at 25-26 weeks of gestation (see "Statistical analysis" section and Table 5) , and was more pronounced as term approached (Figures 2 and 3) .
Plasma sVEGFR-2 concentrations are decreased 6-10 weeks prior to the clinical manifestation of preeclampsia (backward analysis)
Plasma samples of patients with preeclampsia at different gestational ages were stratified according to the interval from blood sampling to clinical diagnosis into 5 groups: at clinical diagnosis; and 2-6, 6-10, 11-15, and Ͼ15 weeks before diagnosis. Plasma samples from healthy pregnant women were matched for gestational age with the plasma samples of patients with preeclampsia at different gestational ages according to the intervals specified above (eg, 2-6 weeks before diagnosis). The median plasma sVEGFR-2 concentration was significantly lower in patients who developed preeclampsia than in healthy pregnant women at clinical diagnosis, 2-6 weeks, and 6-10 weeks before the clinical diagnosis (all P Յ .001) ( Table 6 ). There were 23 plasma samples available from women with preeclampsia at the time of diagnosis. Among patients with preeclampsia, those who delivered neonates whose birthweight was Ͻ10th percentile for gestational age had a significantly lower median plasma sVEGFR-2 concentration than those who delivered neonates whose birthweight was above 10th percentile for gestational age (Ͼ10th percentile [n ϭ 17]: median, 7.5 ng/mL, range, 5.1-11.3 ng/mL vs Ͻ10th percentile [n ϭ 6]: median, 5.2 ng/mL; range, 3.7-7.7 ng/mL; P ϭ .01). In contrast, there was no significant difference in the median plasma concentration of sVEGFR-2 between patients with mild and those with severe preeclampsia (mild [n ϭ 10]: median, 6.1 ng/mL; range, 3.7-11.3 ng/mL vs severe [n ϭ 13]: median, 7.5 ng/mL; range, 4.3-8.5 ng/mL; P ϭ .4). Women with early-onset Patients destined to develop preeclampsia (PE) had significantly different profile (plasma concentration over time) of plasma sVEGFR-2 concentration from controls after adjusting for GA at blood sampling, maternal age, body mass index, nulliparous status, history of PE, smoking, and duration of sample storage (P ϭ .047). Plasma sVEGFR-2 concentration was lower in patients with PE than in healthy pregnant women from approximately 16-20 weeks of gestation and more pronounced as term approached.
GA, gestational age; sVEGFR-2, soluble vascular endothelial growth factor receptor-2.
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Obstetrics Research preeclampsia had a lower median plasma concentration of sVEGFR-2 at clinical manifestation than those with late-onset disease (early onset [n ϭ 6]: median, 5.5 ng/mL; range, 3.7-6.9 ng/mL vs late onset [n ϭ 17]: median, 7.7 ng/mL; range, 5.1-11.3 ng/mL; P ϭ .01). Power analysis indicated that this study had a power of 80% with an alpha of 0.05 (2-tailed) to detect the effect size of 11.9%, 11.4%, and 12.9% in the first (6-14.9 weeks), second (15-19.9 weeks), and third (20-24.9 weeks) gestational age intervals, respectively.
COMMENT
Principal findings
The study has 3 principal findings. First, mothers destined to develop preeclampsia have lower plasma sVEGFR-2 concentrations than those who eventually had a normal pregnancy from 25-26 weeks of gestation, and were more pronounced as term approached (longitudinal analysis). Second, backward analysis suggested that the change starts approximately 6-10 weeks prior to the clinical diagnosis (cross-sectional approach). Third, low plasma sVEGFR-2 concentrations (below the first quartile) at 28-31 and 32-36 weeks of gestation conferred the risk of developing preeclampsia later.
Plasma sVEGFR-2 concentrations are decreased prior to the clinical manifestation of preeclampsia
Our findings are novel and consistent with previous observations at the time of the clinical manifestation of preeclampsia. 47, 49 This result is in contrast to a study that reported that there was no significant difference in the mean serum concentration of sVEGFR-2 between patients diagnosed with preeclampsia and women with normal pregnancies. 31 However, only 15 patients were included in that study. Indeed, the decrease in plasma sVEGFR-2 concentrations in women destined to develop preeclampsia becomes statistically significant 6-10 weeks prior to the clinical manifestation, which is approximately the same time that the increases in plasma concentrations of sVEGFR-1 have been observed. 23 In the current study, early-onset preeclampsia was associated with lower plasma sVEGFR-2 concentrations than the late-onset disease, which is also consistent with our previous study in an African American population. 49 Collectively, plasma sVEGFR-2 concentrations in preeclampsia follow the same trend as that of sVEGFR-1, but in an opposite direction. However, the magnitude of the change in the median plasma sVEGFR-2 concentration (10-57%) in patients with preeclampsia compared to that of healthy pregnant women is less than that observed in plasma sVEGFR-1 concentrations (2.5-to 10-fold).
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The roles of sVEGFR-2 in VEGFsignaling system in the nonpregnant state
Although VEGF can bind sVEGFR-1 with a 10-fold higher affinity than sVEGFR-2, 20 the plasma concentration of sVEGFR-2 was Ͼ10-fold higher than that of sVEGFR-1. 46 It remains to be determined if sVEGFR-2 acts as an antagonist to VEGF in the nonpregnant state. In contrast to sVEGFR-1, the roles and regulation of sVEGFR-2 are unclear. Three recent studies have helped elucidate the functions and regulations of this protein.
First, a study in nonpregnant patients with dengue hemorrhagic fever 46 indicated that VEGF activity may be reflected by plasma sVEGFR-2 concentrations. While the mean plasma VEGF concentration in these patients increased during illness, plasma sVEGFR-2 concentrations declined dramatically until the time of plasma leakage, and then increased during the convalescent phase of the disease. Importantly, the decrease in plasma concentrations of sVEGFR-2 paralleled that of sVEGFR-2-VEGF complexes, and was associated with both an increase in free VEGF and the onset of plasma leakage. This is the first evidence that sVEGFR-2 can bind to VEGF in humans. 46 Moreover, the temporal association between the decline in sVEGFR-2 concentrations and the increase in VEGFR-2 expression on endothelial cells suggests that sVEGFR-2 is a proteolytic product of the membranous form. 46 The authors concluded that a plasma factor from the host in response to dengue vi- 
Individual changes in sVEGFR-2 concentrations
Individual changes in maternal plasma concentration (log10 ϩ 1) of soluble vascular endothelial growth factor receptor (sVEGFR)-2 in normal pregnant women (n ϭ 160) and patients destined to develop preeclampsia (n ϭ 40) as a function of gestational age (GA). rus increased the expression of VEGFR-2 on endothelial cells and decreased shedding of this receptor. 46 Second, another study in the field of cancer proposed a different etiology for decreased circulating sVEGFR-2. Using an experimental model of tumor xenografts on mice, Ebos et al 53 reported an inverse relationship between tumor size and plasma sVEGFR-2 concentration, which was induced by tumor-derived VEGF. Further experiments on human umbilical vein endothelial cells indicate that VEGF can induce down-regulation of VEGFR-2 expression on endothelial cells and concomitantly decrease the soluble form of VEGFR-2 in condition media. 53 Third, antiangiogenic therapy has been an area of active investigation in the field of cancer. After receiving antiangiogenic drugs interfering with VEGF signaling, cancer patients frequently developed hypertension, proteinuria, and rarely thrombosis, 20, 54 clinical features similar to those observed in patients with preeclampsia. However, there is an increase in plasma concentrations of VEGF and PlGF, but a decrease in plasma sVEGFR-2 concentrations in these patients. [55] [56] [57] A recent experimental study found similar changes in plasma concentrations of VEGF, PlGF, and sVEGFR-2 in nontumor-bearing animals after injection of this class of drugs (multitargeted receptor tyrosine kinase inhibitor), suggesting that these side effects are not related to the tumor. 54 These animals had an increased expression of VEGF, but a decreased expression of VEGFR-2 in several organs including liver, heart, spleen, kidney, bone marrow, and skin, 54 suggesting that the antiangiogenic state induced by exogenous drugs in healthy individuals may temporarily induce changes in expression of VEGF and VEGFR-2 in multiple organs as well as a decrease in plasma sVEGFR-2 concentration.
Possible explanation for decreased plasma sVEGFR-2 concentrations in preeclampsia
Healthy pregnant women had a different profile of angiogenic factors than nonpregnant women. The roles and regulation of sVEGFR-2 during pregnancy may be different from that of nonpregnant women. The decrease in plasma sVEGFR-2 concentrations in preeclampsia is unlikely to be explained by an increased binding of sVEGFR-2 to VEGF since there is an abundance of sVEGFR-1, which has a much higher affinity to VEGF than sVEGFR-2. However, it is possible that there is an increased VEGFR-2 expression in response to a depleted availability of free VEGF in preeclampsia, and thus decreased shedding of this receptor.
Similarly, the low plasma sVEGFR-2 concentrations in preeclampsia could not be explained by the VEGF-induced down-regulation of VEGFR-2 receptors since plasma free VEGF concentrations in preeclampsia are lower than those in 
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Obstetrics Research normal pregnancy. Finally, preeclampsia is an antiangiogenic state with an excess of antiangiogenic factors released into the maternal circulation by the placenta, which could induce increased VEGF expression and decreased VEGFR-2 expression in several organs. Indeed, plasma concentrations of total VEGF in preeclampsia are increased compared to those in normal pregnancy.
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Plasma sVEGFR-2 concentrations as a biomarker for the identification of patients destined to develop preeclampsia
Although the decline in plasma sVEGFR-2 concentrations in preeclampsia began as early as 16 weeks, the departure from the trend of normal pregnancy became statistically significant at 25-26 weeks by a longitudinal approach and at 28-32 weeks of gestation by cross-sectional analysis. Low plasma sVEGFR-2 concentrations (below the first quartile) at 28-36 weeks of gestation conferred only mild to moderate risk (odds ratio of 3-5) for women to develop preeclampsia. These findings make plasma sVEGFR-2 unlikely to be an isolated, early biomarker for the prediction of preeclampsia. It remains to be determined if a combination of sVEGFR-2 and other angiogenic/antiangiogenic factors could improve the prediction or risk assessment of women destined to develop preeclampsia.
Strengths and limitations
This study is the first to examine plasma concentrations of sVEGFR-2 before the clinical diagnosis of preeclampsia. Moreover, the potential role of sVEGFR-2 as a new biomarker for the prediction of preeclampsia was evaluated throughout pregnancy. Furthermore, both cross-sectional and longitudinal approaches were employed for the analysis of the data allowing us to determine the different profiles of plasma sVEGFR-2 concentrations in preeclampsia and normal pregnancy in relation to gestational age. The limitation of this study is that all patients enrolled in this study were of Hispanic origin. Thus, it remains to be determined if the changes in plasma sVEGFR-2 concentrations reported herein can be replicated in different ethnic groups.
In conclusion, our study demonstrates that plasma sVEGFR-2 concentration in women destined to develop preeclampsia is lower than that of healthy pregnant women approximately 6-10 weeks prior to the clinical manifestation. This decline is more pronounced as the patient approaches the time of clinical diagnosis both at term and preterm. This observation suggests that sVEGFR-2 may be involved in the pathophysiology of preeclampsia.
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